Mediolanum International Funds Ltd Sells 945 Shares of Qiagen (NYSE:QGEN)

Mediolanum International Funds Ltd cut its holdings in Qiagen (NYSE:QGEN) by 10.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,733 shares of the company’s stock after selling 945 shares during the period. Mediolanum International Funds Ltd’s holdings in Qiagen were worth $351,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of QGEN. Massmutual Trust Co. FSB ADV grew its position in shares of Qiagen by 39.8% in the third quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares in the last quarter. CWM LLC grew its holdings in Qiagen by 12.0% during the 2nd quarter. CWM LLC now owns 2,505 shares of the company’s stock valued at $103,000 after buying an additional 269 shares in the last quarter. Private Advisor Group LLC increased its position in shares of Qiagen by 8.0% during the third quarter. Private Advisor Group LLC now owns 6,251 shares of the company’s stock valued at $285,000 after buying an additional 461 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Qiagen by 806.5% in the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock worth $26,000 after buying an additional 500 shares in the last quarter. Finally, Sequoia Financial Advisors LLC boosted its position in shares of Qiagen by 2.8% in the third quarter. Sequoia Financial Advisors LLC now owns 18,618 shares of the company’s stock valued at $848,000 after acquiring an additional 511 shares during the period. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Stock Performance

Qiagen stock opened at $41.55 on Monday. The firm has a fifty day simple moving average of $44.68 and a two-hundred day simple moving average of $43.56. Qiagen has a twelve month low of $34.74 and a twelve month high of $47.44. The company has a market capitalization of $9.48 billion, a PE ratio of 27.89, a P/E/G ratio of 3.22 and a beta of 0.39. The company has a quick ratio of 1.46, a current ratio of 1.77 and a debt-to-equity ratio of 0.27.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.52 by $0.03. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The business had revenue of $496.00 million for the quarter, compared to analyst estimates of $495.45 million. During the same period last year, the company earned $0.53 EPS. Qiagen’s revenue for the quarter was down .2% compared to the same quarter last year. Research analysts expect that Qiagen will post 2.15 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on QGEN shares. HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a research report on Thursday, October 17th. Robert W. Baird boosted their target price on Qiagen from $49.00 to $52.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Finally, Hsbc Global Res raised Qiagen to a “hold” rating in a report on Thursday, October 17th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $50.12.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.